BRPI1008008A2 - usos de antagonistas do receptor de nk - Google Patents

usos de antagonistas do receptor de nk

Info

Publication number
BRPI1008008A2
BRPI1008008A2 BRPI1008008A BRPI1008008A BRPI1008008A2 BR PI1008008 A2 BRPI1008008 A2 BR PI1008008A2 BR PI1008008 A BRPI1008008 A BR PI1008008A BR PI1008008 A BRPI1008008 A BR PI1008008A BR PI1008008 A2 BRPI1008008 A2 BR PI1008008A2
Authority
BR
Brazil
Prior art keywords
receptor antagonists
antagonists
receptor
Prior art date
Application number
BRPI1008008A
Other languages
English (en)
Inventor
Anton Stuetz
Barbara Wolff-Winiski
Lina Williamson
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42102184&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008008(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI1008008A2 publication Critical patent/BRPI1008008A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI1008008A 2009-02-24 2010-02-23 usos de antagonistas do receptor de nk BRPI1008008A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15497309P 2009-02-24 2009-02-24
PCT/EP2010/052273 WO2010097381A1 (en) 2009-02-24 2010-02-23 Uses of nk receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI1008008A2 true BRPI1008008A2 (pt) 2016-02-23

Family

ID=42102184

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008008A BRPI1008008A2 (pt) 2009-02-24 2010-02-23 usos de antagonistas do receptor de nk

Country Status (17)

Country Link
US (1) US20120077803A1 (pt)
EP (1) EP2400953A1 (pt)
JP (1) JP5425229B2 (pt)
KR (1) KR20110118830A (pt)
CN (1) CN102395358A (pt)
AU (1) AU2010217615C1 (pt)
BR (1) BRPI1008008A2 (pt)
CA (1) CA2753330A1 (pt)
CL (1) CL2011002045A1 (pt)
EA (1) EA201101207A1 (pt)
IL (1) IL214731A0 (pt)
MA (1) MA33059B1 (pt)
MX (1) MX2011008878A (pt)
SG (1) SG173758A1 (pt)
TN (1) TN2011000428A1 (pt)
TW (1) TW201034674A (pt)
WO (1) WO2010097381A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201590364A1 (ru) * 2012-10-11 2015-11-30 Нерр Терапьютикс Лимитед Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8906951B1 (en) 2013-06-24 2014-12-09 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
US9198898B2 (en) 2013-06-24 2015-12-01 Tigercat Pharma, Inc. Use of NK-1 receptor antagonists in pruritus
MX2018016400A (es) * 2016-06-29 2019-09-02 Menlo Therapeutics Inc Uso de antagonistas de neuroquinina 1 para tratar una variedad de afecciones pruríticas.
IL318587A (en) 2018-07-23 2025-03-01 Trevi Therapeutics Inc Treatment of chronic cough, shortness of breath and wheezing
CA3166928A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2728166A1 (fr) * 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2740040B1 (fr) * 1995-10-23 1997-12-05 Oreal Utilisation d'au moins un agoniste beta-adrenergique en tant qu'antagoniste de substance p
DE19541283A1 (de) * 1995-11-06 1997-05-07 Boehringer Ingelheim Kg Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
MY132550A (en) * 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
JP3793612B2 (ja) * 1996-11-28 2006-07-05 花王株式会社 皮膚外用剤
CA2432543A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Combination drugs
JP2003238986A (ja) * 2002-02-22 2003-08-27 Shiseido Co Ltd サブスタンスｐ増加抑制剤
ITFI20030113A1 (it) * 2003-04-24 2004-10-25 Menarini Ricerche Spa Composti lineari nk-2 antagonisti con caratteristiche basiche e formulazioni che li contengono.
JO2630B1 (en) * 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
KR20090071581A (ko) * 2006-10-16 2009-07-01 라이온 가부시키가이샤 Ｎｋ１ 수용체 앤태고니스트 조성물
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
US20100316678A1 (en) * 2007-06-28 2010-12-16 Cnsbio Pty Ltd. Combination methods and compositions for treatment of neuropathic pain

Also Published As

Publication number Publication date
US20120077803A1 (en) 2012-03-29
SG173758A1 (en) 2011-09-29
WO2010097381A1 (en) 2010-09-02
CL2011002045A1 (es) 2012-01-13
JP5425229B2 (ja) 2014-02-26
CA2753330A1 (en) 2010-09-02
IL214731A0 (en) 2011-11-30
JP2012518622A (ja) 2012-08-16
AU2010217615A1 (en) 2011-09-08
KR20110118830A (ko) 2011-11-01
TW201034674A (en) 2010-10-01
AU2010217615C1 (en) 2013-05-23
MA33059B1 (fr) 2012-02-01
TN2011000428A1 (en) 2013-03-27
CN102395358A (zh) 2012-03-28
EA201101207A1 (ru) 2012-04-30
MX2011008878A (es) 2011-09-21
EP2400953A1 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
HUS2200033I1 (hu) CGRP receptor antagonisták
CY2023022I1 (el) Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης
PT3091012T (pt) Antagonistas do receptor ccr2 e suas utilizações
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
PL2927224T3 (pl) Antagoniści receptora
EP2480576A4 (en) PCSK9 ANTAGONISTS
BRPI0910118A2 (pt) antagonistas de receptores do glucagon
BR112014001030A2 (pt) anticorpos anti-receptor alfa de folato e usos destes
SMT201600078B (it) Antagonista del recettore per cgrp
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BR112012003263A2 (pt) formulações intravenosas de antagonistas de neuroquinina-1
EP2350060A4 (en) Melanocortin receptor AGONISTS
DK2501703T3 (da) Spiropiperidinforbindelser som orl-1-receptorantagonister
DK2501704T3 (da) Spiropiperidinforbindelser som oral-1-receptorantagonister
ME02965B (me) Kombinacije antagonista muskarinskog receptora i agonista вета - 2 adrenoreceptora
HUE063115T2 (hu) Kiméra I-es típusú IL-1 receptor antagonisták
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
IL214731A0 (en) Uses of nk receptor antagonists
BR112012003976A2 (pt) antagonistas de receptor glyt1 carbocíclico
BRPI1013617A2 (pt) derivados de piperidina como antagonistas de receptor de nk3
BRPI0915834A2 (pt) 6-(1-piperazinil)-piridazinas substituídas como antagonistas do receptor de 5-ht6
BRPI1014668A2 (pt) antagonistas ccr3 de arilsulfonamida
EP2539706A4 (en) ARYLPIPERAZON-OPIOID RECEPTOR ANTAGONISTS
BR112012005119A2 (pt) novos antagonistas de hepcidina etanodiaminas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.